Shares in Ultragenyx and Mereo BioPharma have plunged after their drug for osteogenesis imperfecta (OI) or brittle bone ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Newland, CEO of ANGLE, about why live cell liquid ...

The NHS has an extraordinary opportunity in 2026. Unified data, decision intelligence, and strong workforce capability can ...

In 2026, we will see widespread adoption of AI tools that automate time-consuming administrative tasks: drafting clinical ...

Judge Lance Walker sided with the American Hospital Association (AHA) and other plaintiffs in the lawsuit, brought in a Maine ...

Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...

Bevacizumab has been sold as Avastin by originator Roche for many years and used by the NHS for various forms of cancer, with ...

That scuppered Sanofi's plans for filing tolebrutinib in PPMS, and the FDA has now slammed the brakes on its efforts to get ...

To begin to close the equity gap in diabetes, we must commit to designing therapies that account for the practical realities ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Vinay Patel, an innovative pharmacist who's set out to ...

The French pharma major has started a $15.50 per share cash tender offer for Emeryville, California-based Dynavax, which ...

"Our goal in the LATIFY trial was to reinvigorate the immune response of patients with lung cancer whose tumours stopped ...